Axcan kept at neutral by Merrill

Merrill Lynch analyst Hari Sambasivam maintained Axcan Pharma Inc. at neutral. The analyst's estimates for the quarter include total product revenues of $68.4 million and pro forma net income of $9.4 million, or $0.17 per share. Consensus earnings per share for the quarter were $0.16. Merrill's prescription tracker suggests stable or modest prescription growth for Axcan's major products. Shares of the Mount-Saint-Hilaire, Quebec, pharmaceutical company were down 11 cents, or 0.81%, at $13.42 on volume of 314,674 shares versus the three-month running average of 629,971 shares. (Nasdaq: AXCA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.